With little more than a month to go until the national election, President Trump announced a revised initiative designed to reduce what consumers pay for prescription drugs, while also promising to protect coverage for pre-existing health conditions.
FDA and EMA have accepted the biologics license application and marketing authorization application, respectively, for bimekizumab.
Telstar has reinforced its consultancy service to aid pharmaceutical companies in the compliance of the latest version of the EU GMP Annex 1 guidance.
The Korean MFDS has given its approval for Celltrion to initiate a Phase II/III trial of its anti-COVID-19 monoclonal antibody treatment candidate, CT-P59.
ISPE has released new guidance on the cleaning validation lifecycle, written by a group of experts and reviewed by regulators and practitioners.
Fears about overly accelerated development programs has heightened demands for wider access to information on study protocols, statistical analysis plans, and early results.
The guidance document offers information on the placement and content of geriatric information in labeling of drugs and biologics.
The agency’s human medicines committee is endorsing the use of dexamethasone in COVID-19 patients requiring oxygen therapy.
The EMA recommendations include a meningococcal vaccine and the biosimilar Nyvepria.
The agency sent a warning letter to Kalchem International for CGMP violations found at the company’s Lindsay, OK, facility.
GenSight Biologics has submitted a marketing authorization application to the European Medicines Agency for Lumevoq.
The temporary guidance discusses the resumption of normal manufacturing during the COVID-19 pandemic.
In an opinion article, FDA leaders commit to applying “the best science” to approval decisions.
PRAC has recommended the marketing authorization of ulipristal acetate for the treatment of uterine fibroids be revoked.
Imfinzi has been granted approval in the EU for the treatment of adults with extensive-stage small cell lung cancer.
As public confidence in the drug development process waivers, leading vaccine developers promise to adhere to scientific and regulatory principles.
Industry leaders insist they will maintain high standards for clinical trials and regulatory submissions for new vaccines and therapeutics to combat COVID-19.
Despite pharmacovigilance legislation being in place for nearly a decade, many companies are still struggling to fulfill obligations.
Regulators strive to review flood of advanced treatments while also vetting COVID-19 vaccines.
The 2020–2025 EMRN strategy will be regularly reviewed over the coming five years to accommodate science and technology advances.
An assessment can identify the critical systems and the gaps in compliance based on intended use, says Siegfried Schmitt, vice president technical, Parexel.
The guidance recommends steps to detect and prevent nitrosamine impurities in pharmaceutical products.
The agency is reviewing an application for Dexamethasone Taw for treating adult patients with COVID-19.
The agency sent a warning letter to Acella Pharmaceuticals detailing CGMP violations and failures to oversee contract manufacturers.
The agency sent a warning letter after an inspection of the company’s Sangareddy District, India found inadequate cleaning procedures.
